<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31974576</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1469-5111</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Apr</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>The international journal of neuropsychopharmacology</Title>
          <ISOAbbreviation>Int J Neuropsychopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.</ArticleTitle>
        <Pagination>
          <StartPage>217</StartPage>
          <EndPage>229</EndPage>
          <MedlinePgn>217-229</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/ijnp/pyaa004</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Different effectiveness profiles among antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to impact on long-term outcome. The aim of this study is to compare the clinical effectiveness of olanzapine, risperidone, haloperidol, aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year follow-up.</AbstractText>
          <AbstractText Label="METHOD">From February 2001 to January 2011, 2 phases of a prospective, randomized, open-label study were undertaken. A total of 376 first-episode drug-naïve patients were randomly assigned to olanzapine (n = 55), risperidone (n = 63), haloperidol (n = 56), aripiprazole (n = 78), ziprasidone (n = 62), or quetiapine (n = 62) and followed up for 3 years. The primary effectiveness measure was all cause of treatment discontinuation. In addition, an analysis based on intention-to-treat principle was conducted in the analysis for clinical efficacy.</AbstractText>
          <AbstractText Label="RESULTS">The overall dropout rate at 3 years reached 20.75%. Treatment discontinuation rates were significantly different among treatment groups (olanzapine = 69.09, risperidone = 71.43, aripiprazole = 73.08%, ziprasidone = 79.03%, haloperidol = 89.28%, and quetiapine = 95.53%) (χ2 = 79.86; P = .000). Statistically significant differences in terms of lack of efficacy, adherence, and tolerability were observed among treatment groups along the 3-year follow-up, determining significant differences in time to all-cause discontinuation (log-rank = 92.240; P = .000). Significant differences between treatments were found in the categories of sleepiness/sedation, increased sleep duration, akinesia, weight gain, ejaculatory dysfunction, extrapyramidal-symptoms, and amenorrhea.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Olanzapine, risperidone, and aripiprazole presented advantages for the first-line treatment of first episode of psychosis in terms of effectiveness. Identifying different discontinuation patterns may contribute to optimize treatment selection after first episode of psychosis.ClinicalTrials.gov Identifier: NCT02526030 https://clinicaltrials.gov/show/NCT02526030.</AbstractText>
          <CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press on behalf of CINP.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gómez-Revuelta</LastName>
            <ForeName>Marcos</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pelayo-Terán</LastName>
            <ForeName>José María</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Servicio de Psiquiatría y Salud Mental. Hospital El Bierzo. Servicio de Salud de Castilla y León (SACYL), Ponferrada (León), Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Juncal-Ruiz</LastName>
            <ForeName>María</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sierrallana Hospital, Department of Psychiatry, IDIVAL, School of Medicine, University of Cantabria, Torrelavega, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vázquez-Bourgon</LastName>
            <ForeName>Javier</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Suárez-Pinilla</LastName>
            <ForeName>Paula</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Romero-Jiménez</LastName>
            <ForeName>Rodrigo</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Setién Suero</LastName>
            <ForeName>Esther</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ayesa-Arriola</LastName>
            <ForeName>Rosa</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Crespo-Facorro</LastName>
            <ForeName>Benedicto</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hospital Universitario Virgen del Rocío, Department of Psychiatry, Universidad de Sevilla, Sevilla, Spain. Instituto de Investigacion Sanitaria de Sevilla, IBiS.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02526030</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Neuropsychopharmacol</MedlineTA>
        <NlmUniqueID>9815893</NlmUniqueID>
        <ISSNLinking>1461-1457</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2S3PL1B6UJ</RegistryNumber>
          <NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6UKA5VEJ6X</RegistryNumber>
          <NameOfSubstance UI="C092292">ziprasidone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82VFR53I78</RegistryNumber>
          <NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>J6292F8L3D</RegistryNumber>
          <NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>L6UH7ZF8HC</RegistryNumber>
          <NameOfSubstance UI="D018967">Risperidone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N7U69T4SZR</RegistryNumber>
          <NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">antipsychotics</Keyword>
        <Keyword MajorTopicYN="Y">first-episode-psychosis</Keyword>
        <Keyword MajorTopicYN="Y">schizophrenia</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31974576</ArticleId>
        <ArticleId IdType="pmc">PMC7177160</ArticleId>
        <ArticleId IdType="doi">10.1093/ijnp/pyaa004</ArticleId>
        <ArticleId IdType="pii">5715030</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Addington D, Addington J, Maticka-Tyndale E (1993) Assessing depression in schizophrenia: the Calgary depression scale. Br J Psychiatry 163(Suppl 22):
39–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8110442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Andreasen N. (1984) The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: Univ Iowa.</Citation>
        </Reference>
        <Reference>
          <Citation>
Andreasen NC. (1989) Scale for the assessment of negative symptoms (SANS). Br J Psychiatry 155:53–58.</Citation>
        </Reference>
        <Reference>
          <Citation>
Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S (2013) Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev Advance online publication. http://doi.wiley.com/10.1002/14651858.CD006625.pub3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD006625.pub3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barnes TR. (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2574607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Correll CU, De Hert M (2013) Antipsychotics for acute schizophrenia: making choices. Lancet 382:919–920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23810018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Correll CU, Rubio JM, Kane JM (2018) What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry 17:149–160. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5980517</ArticleId>
            <ArticleId IdType="pubmed">29856543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Crespo-Facorro B, Pérez-Iglesias R, Mata I, Caseiro O, Martínez-Garcia O, Pardo G, Ramirez-Bonilla M, Pelayo-Terán JM, Vázquez-Barquero JL (2011) Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine. J Psychiatr Res 45:763–769.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21106207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Crespo-Facorro B, Pérez-Iglesias R, Mata I, Martínez-Garcia O, Ortiz V, Pelayo-Terán JM, Valdizan E, Vazquez-Barquero JL (2012) Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. Psychopharmacology (Berl) 219:225–233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21735072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Crespo-Facorro B, de la Foz VO, Mata I, Ayesa-Arriola R, Suarez-Pinilla P, Valdizan EM, Martinez-Garcia O, Pérez-Iglesias R (2014) Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year. Psychopharmacology (Berl) 231:357–366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23958945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Crespo-Facorro B, Pelayo-Teran JM, Mayoral-van Son J (2016) Current data on and clinical insights into the treatment of first episode nonaffective psychosis: a comprehensive review. Neurol Ther 5:105–130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5130917</ArticleId>
            <ArticleId IdType="pubmed">27553839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Davy V, Correll CU, Britta G, Michel P, Marc DH, Ward PB, Simon R, Fiona G, John L, Brendon S (2016) Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis. World Psychiatry 15:166–174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4911762</ArticleId>
            <ArticleId IdType="pubmed">27265707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Emsley R, Chiliza B, Asmal L, Harvey BH (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13:50 Advance online publication. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3599855&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3599855</ArticleId>
            <ArticleId IdType="pubmed">23394123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured clinical interview for DSM-IV-TR axis I disorders research version, patient edition with psychotic screen (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute.</Citation>
        </Reference>
        <Reference>
          <Citation>
Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, Ortiz-García de la Foz V, Vázquez-Bourgon J, González-Pinto A, Crespo-Facorro B (2018) Long-term antipsychotic effectiveness in first episode of psychosis: a 3-year follow-up randomized clinical trial comparing aripiprazole, quetiapine, and ziprasidone. Int J Neuropsychopharmacol 21:1090–1101. Advance online publication. https://academic.oup.com/ijnp/advance-article/doi/10.1093/ijnp/pyy082/5095916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ijnp/pyy082/5095916</ArticleId>
            <ArticleId IdType="pmc">PMC6276055</ArticleId>
            <ArticleId IdType="pubmed">30215723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Guy W. (1976) ECDEU Assessment Manual for Psychopharmacology: revised. Rockville: National Institute of Mental Health.</Citation>
        </Reference>
        <Reference>
          <Citation>
Jann MW, Penzak SR (2018) Long-acting injectable second-generation antipsychotics: an update and comparison between agents. CNS Drugs 32:603. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29569082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Johnsen E, Kroken RA, Wentzel-Larsen T, Jørgensen HA (2010) Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry 10:26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2851682</ArticleId>
            <ArticleId IdType="pubmed">20334680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Juncal-Ruiz M, Ramirez-Bonilla M, Gomez-Arnau J, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Martinez-Garcia O, Neergaard KD, Tabares-Seisdedos R, Crespo-Facorro B (2017) Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. Psychopharmacology (Berl) 234:2563–2570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28567698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE (2008a) 
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085–1097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18374841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kahn RS, Wolfgang Fleischhacker W, Boter H, Davidson M, Vergouwe Y, M Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE (2008b) 
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085–1097. [DOUBLE REFERENCE (a and b)]</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18374841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU (2014) Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 40:192–213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3885289</ArticleId>
            <ArticleId IdType="pubmed">23256986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU (2019) Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry 18:208–224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6502423</ArticleId>
            <ArticleId IdType="pubmed">31059621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lako IM, van den Heuvel ER, Knegtering H, Bruggeman R, Taxis K (2013) Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol 33:675–681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23948784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee SY, Park MH, Patkar AA, Pae CU (2011) A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry 35:490–496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21146575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19015230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23810019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators  (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16172203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lindström L, Lindström E, Nilsson M, Höistad M(2017) Maintenance therapy with second generation antipsychotics for bipolar disorder–A systematic review and meta-analysis. J Affect Disord 213:138–150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28222360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K(1987) The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients. Acta Psychiatr Scand 76:1–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2887090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mayoral-van Son J, de la Foz VO, Martinez-Garcia O, Moreno T, Parrilla-Escobar M, Valdizan EM, Crespo-Facorro B (2016) Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study. J Clin Psychiatry 77:492–500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26759992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD (2007) Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164:1050–1060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17606657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812.</Citation>
        </Reference>
        <Reference>
          <Citation>
Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M, González-Blanch C, Martínez-García O, Pardo-García G, Rodríguez-Sánchez JM, Roiz-Santiáñez R, Tordesillas-Gutiérrez D, Mata I, Vázquez-Barquero JL, Crespo-Facorro B (2008) Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the clinical programme on early phases of psychosis. Early Interv Psychiatry 2:178–187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21352151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pelayo-Terán JM, Gajardo Galán VG, de la Ortiz-García de la Foz V, Martínez-García O, Tabarés-Seisdedos R, Crespo-Facorro B, Ayesa-Arriola R (2017) Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP). Eur Arch Psychiatry Clin Neurosci 267:315–323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27796500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pelayo-Terán JM, Gajardo-Galán V, Gómez-Revuelta M, Ortiz-García de la Foz V, Ayesa-Arriola R, Tabarés-Seisdedos R, Crespo-Facorro B (2018) Duration of active psychosis and functional outcomes in first-episode non-affective psychosis. Eur Psychiatry 52:29–37.</Citation>
        </Reference>
        <Reference>
          <Citation>
Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M, Lambert M, Lin CH, Möller HJ, Pelayo-Terán JM, Riedel M, Rujescu D, Schimmelmann BG, Serretti A, Correll CU, Leucht S (2015) Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 172:617–629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26046338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4917967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K (2008) First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 192:406–411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18515889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Smith RC, Leucht S, Davis JM (2019) Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Psychopharmacology (Berl) 236:545–559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30506237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Takeuchi H, Siu C, Remington G, Fervaha G, Zipursky RB, Foussias G, Agid O (2019) Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology 44:1036–1042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6462044</ArticleId>
            <ArticleId IdType="pubmed">30514883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, Taipale H (2017) Real-world effectiveness of antipsychotic treatments in a nationwide Cohort of 29 823 patients with schizophrenia. JAMA Psychiatry 74:686–693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5710250</ArticleId>
            <ArticleId IdType="pubmed">28593216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vanasse A, Blais L, Courteau J, Cohen AA, Roberge P, Larouche A, Grignon S, Fleury MJ, Lesage A, Demers MF, Roy MA, Carrier JD, Delorme A (2016) Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatr Scand 134:374–384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27404582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vázquez-Bourgon J, Pérez-Iglesias R, Ortiz-García de la Foz V, Suárez Pinilla P, Díaz Martínez Á, Crespo-Facorro B (2018) Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis. Psychopharmacology (Berl) 235:245–255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29075885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang C, Shi W, Huang C, Zhu J, Huang W, Chen G(2017) The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial. Ann Gen Psychiatry 16:47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5740943</ArticleId>
            <ArticleId IdType="pubmed">29299043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woods SW. (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64:663–667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12823080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">728692</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
